Medication info
Sevim HCT Tablet 5/20/12.5 mg

Sevim HCT Tablet 5/20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
White-orange round film-coated tablet
Packaging
30 tablets (10 tablets/Alu-Alu × 3)
Approval status
Active

MFDS item code 201902991 · Approved 2019.05.09 · Insurance code 622803490

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy with amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 5/20mg amlodipine/olmesartan medoxomil. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 5/40mg amlodipine/olmesartan medoxomil or with 5/20/12.5mg of this medicine. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with 5/40/12.5mg of this medicine. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 10/40mg amlodipine/olmesartan medoxomil or with 5/40/12.5mg of this medicine. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with 5/40/25mg or 10/40/12.5mg of this medicine. ※ Refer to the following dose escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years or older) In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with use of this medicine in elderly patients aged 75 years or older, monitor them very carefully during treatment.
Child dose
The safety and efficacy of this medicine in pediatric patients younger than 18 years have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy with amlodipine and olmesartan

  • Essential hypertension
View approved original text

The combination therapy of Amlodipine and Olmesartan Medoxomil is used when blood pressure control is difficult or ineffective with monotherapy for patients with essential hypertension, i.e. hypertension of unknown cause. These medications help to expand blood vessels and lower blood pressure, reducing the risk of cardiovascular complications. Combination therapy allows for more effective management of blood pressure and prevents long-term damage to the heart and kidneys, making it a suitable treatment option for patients whose blood pressure is not well controlled.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 5/20mg amlodipine/olmesartan medoxomil. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 5/40mg amlodipine/olmesartan medoxomil or with 5/20/12.5mg of this medicine. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with 5/40/12.5mg of this medicine. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy with 10/40mg amlodipine/olmesartan medoxomil or with 5/40/12.5mg of this medicine. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with 5/40/25mg or 10/40/12.5mg of this medicine. ※ Refer to the following dose escalation schedule. (The amounts of the individual components are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years or older) In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with use of this medicine in elderly patients aged 75 years or older, monitor them very carefully during treatment.

Child dose

The safety and efficacy of this medicine in pediatric patients younger than 18 years have not been established; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so use should be discontinued immediately upon confirmation of pregnancy. Patients with known allergies or hypersensitivity to this drug or its components, pregnant or breastfeeding women, and patients with severe hypotension or heart, kidney, or liver diseases should not use this medication. Patients with reduced blood volume or body sodium may experience symptoms of hypotension upon initial dosing, requiring careful attention and close monitoring of their condition after treatment initiation. Caution is advised with administration in patients with compromised kidney function, kidney transplant patients, those with renovascular hypertension, liver disease, or specific heart conditions, as well as in cases of electrolyte imbalances or certain illnesses. This medication lowers blood pressure and may cause dizziness or lightheadedness, so caution should be exercised when driving or operating hazardous machinery. This medication may interact with other drugs, so patients should consult with their doctor or pharmacist especially if taking lithium, non-steroidal anti-inflammatory drugs, other antihypertensives, certain antibiotics, and other medications. Long-term use requires regular monitoring of serum electrolyte levels and kidney function to detect electrolyte imbalances or renal deterioration early. Breastfeeding women are advised to avoid this medication, and if unavoidable, should discontinue breastfeeding. Safety and efficacy in patients under 18 years of age have not been established, so its use is not recommended. In the event of overdose, cardiovascular symptoms such as hypotension, palpitations, and bradycardia may occur, and immediate medical attention should be sought.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, taste disorders, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, syncope, seizures, loss of appetite, tremors, vision abnormalities, decreased tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, relapse of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasm, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, lumbago, paresis, myalgia, bone pain, polyuria, acute kidney failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated serum urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal bloating, facial flushing, epistaxis, benign prostatic enlargement, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect from air and moisture. Also, it is recommended to store the medication at room temperature between 1°C and 30°C. This helps to maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

White-orange round film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.